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Abstract 
In the 1980’s, medium-chain acyl-CoA dehydrogenase deficiency 
(MCADD) was first described in the literature as three children who presented 
with coma, hypoglycemia, hyperammonemia, and fatty liver while fasting. 
These symptoms while similar to Reye’s Syndrome, were found to be due to 
an inability to metabolize medium chain fatty acids during fasting periods. 
Fatty acids are utilized by the body as essential fuel for skeletal and cardiac 
muscle, and  as an important source of energy during fasting periods. Medium-
chain acyl-CoA dehydrogenase is a mitochondrial enzyme required for the 
beta oxidation of medium chain fatty acids (C4-14), which is deficient in this 
syndrome. Anesthesiologists may come across these patients in their practice, 
as MCADD is the most common inhertited disorder of mitochondrial fatty 
acid oxidation. In addition to determining NPO timing and IV fluid selection, 
other  preoperative issues  anesthesiologists must consider are medication 
management to avoid metabolic decompensation. This manuscript will 
consider a pediatric patient with MCADD who presented to our pediatric 
hospital and received a general anesthetic following the guidelines created by 
our multidisciplinary perioperative team. 
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In 1983, Stanley published a paper in which he 
described three children who presented with coma, 
hypoglycemia, hyperammonemia, and fatty liver 
while fasting (1, 2). These symptoms while similar to 
Reye’s Syndrome, were found to be due to an 
inability to metabolize medium chain fatty acids 
during fasting. As such, Stanley may be credited with 
first publishing medium-chain acyl-CoA 
dehydrogenase deficiency (MCADD) as a previously 
unrecognized metabolic disorder of fatty acid 
oxidation (1, 2). The body utilizes the oxidation of 
fatty acids not only to provide essential fuel for 
skeletal and cardiac muscle, but also as an important 
source of energy during fasting periods (1). While 
fasting, the brain converts fatty acids to energy in 
order to conserve glucose levels. The liver will 
oxidize fatty acids to ketones to servea dual purpose: 
to provide energy for gluconeogenesis, and generating 
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fat derived substrates to support the brain’s metabolic 
requirements in lieu of glucose (1).  
Medium-chain acyl-CoA dehydrogenase is a 
mitochondrial enzyme required for the beta oxidation 
of medium chain fatty acids (C4-14) (3, 4). During 
fasting, adipose tissue will mobilize fatty acids which 
are then absorbed by the liver and other tissues and 
converted to acyl-coA esters (3) intracellularily. 
These esters will then enter the mitochondria as 
carnitine esters and become re-esterified to acyl co-A 
esters. The beta oxidation of the esters will liberate 
electrons as the acyl chain is shortened by an 
enzymatic process (3). The catalysts are acyl-CoA 
dehydrogenases, each specific for very-long chain, 
long-chain, medium-chain, or short chain acyl-co-A 
esters. Figure 1 is a representation of fatty acid beta-
oxidation; medium-chain acyl-CoA dehydrogenase is 
one of the enzymes responsible for the 
dehydrogenation of medium-chain fatty acids.  
Fatty acids normally undergo -oxidation 
during fasting periods to produce ketones. Those with 
MCADD will accumulate fatty acids during fasting, 
and not generate ketones. The systemic consequences 
of MCADD will result in a lack of ketones to meet 
tissue energy demands manifesting as severe 
hypoglycemia as well as toxicity of the liver, muscle, 
and central nervous system as fatty acids and their 
corresponding acylcarnitines accumulate. Hypoketotic 
hypoglycemia will develop in times of fasting 
because of the inability to utilize fat for fuel (2).  
MCADD is the most common inherited 
disorder of mitochondrial fatty acid oxidation (5). It is 
inherited in an autosomal recessive fashion, occurring 
primarily in Caucasians with northern European 
ancestry (2, 3, 5–8). The prevalence has been reported 
to vary by population studied: 1:4,900 in Germany 
and 1:17,000 in Taiwan (9). MCADD occurs with a 
reported incidence of 1 in 12,000- 20,000 births (2, 5, 
9).  
Diagnosis of MCADD can be accomplished by 
DNA analysis for mutations or tissue testing of heart, 
liver, or skeletal muscle for enzyme activity (2, 9). 
Those affected by MCADD are predominantly 
homozygous for a single mutation of an A to G 
nucleotide; the remaining 20% are either carriers of 
the single gene mutation or compound heterozygotes 
(2, 10). As of 2009, the United Kingdom performs 
neonatal screening for MCADD (5). While the 
Discretionary Advisory Council on Heritable 
Disorders in Newborns and Children recommends 
screening for MCADD as a part of the newborn 
screening panel, conditions tested for in the United 
States vary by state (11).  
Typically those affected with MCADD will 
exhibit symptoms between 3 months to 2 years of age 
(mean age 13 months), however neonatal and adult 
presentations have been reported (5, 9, 10). Roughly 
1/3 of affected individuals are asymptomatic 
throughout life, but will remain at risk for metabolic 
decompensation in times of fasting (10). Symptoms of 
MCADD typically manifest after 12-16 hours of 
fasting when glycogen storesare depleted with no 
generation of ketones in times of increased energy 
demands such as: fasting, stress due to surgery, 
pregnancy, illness, or alcohol binge drinking (5, 8). 
Although there is no diagnostic stigmata of MCADD, 
those in acute decompensation may present to 
physicians with hypoketotic hypoglycemia, 
encephalopathy, hepatomegaly, vomiting, seizures, 
coma, or causedeath (5, 9). Table 1 lists the systemic 
consequences of MCADD. Patients with MCADD are 
placed at potential risk for aphasia, loss of 
developmental milestones, and attention deficit 
disorder attributed to brain damage acquired during 
metabolic decompensation (8).  
 There is no specific medical therapy to treat 
MCADD. Patients are advised to limit exacerbations 
by limiting nil per os (NPO) times or fasting, which 
varies by age:  
  1) 6-12 months: No more than 8 hours  
  2) 1-2 years: No more than 10 hours 
  3) 2 years and beyond: No more than 12 
hours (8, 9).  
During times of stress such as fever, illness, or 
fasting those with MCADD should ingest additional 
glucose sources such orange juice or dissolving 
glucose tablets (9). In a  preoperative environment 
intravenous (IV) fluids with dextrose should be 
administered until the patient resumes adequate PO 
intake; point of care glucose testing is not sufficient to 
assess the energy reserves for those with MCADD 
(9). The use of carnitine supplementation is 
controversial though recommended for patients that 
have a low serum carnitine level (9, 12).  
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 In addition, to determining NPO timing and IV 
fluid selection, other  preoperative issues  
anesthesiologists must consider are medication 
management to avoid metabolic 
decompensation.While inhalational agents, propofol, 
andneuromuscular blocking agents are not 
contraindicated in MCADD, they certainly present 
some controversy (2, 5). Some datasuggests an 
impairment of fatty acid metabolism associated with 
anesthetic vapors such as enflurane, thus posing a 
theoretical increased risk during anesthesia (5, 13).  
Cautions in using both depolarizing and non-
depolarizing neuromuscular blockers  preoperatively 
have been made. Patients with MCADD may have 
hypotonia and impaired hepatic metabolism (5, 8); as 
such may have prolonged effects of certain non-
depolarizing agents. Some authors urge caution in the 
use of succinylcholine in the presence of a potential 
myopathy (2).  
Propofol infusion syndrome (PRIS) is defined 
by acute bradycardia progressing to asystole during 
propofol infusion associated with lipoemic plasma, 
fatty liver enlargement, metabolic acidosis, 
rhabdomyolysis, and a base excess > -10 mmol (14). 
PRIS carries an estimated mortality rate of 20%, and 
is thought to be due to impaired fatty acid metabolism 
inhibiting the mitochondrial respiratory chain (5). It 
has been suggested to avoid propofol in patients with 
MCADD and other mitochondrial disorders, due to 
the extra fatty acid contents of the soy bean oil and 
impairment of fatty acid oxidation (4, 5, 15).  
Careful multidisciplinary preoperative planning 
is highly advisable for MCADD patients requiring 
anesthesia. Ideally they should be the first case of the 
day, and preoperative dextrose containing IV fluids 
started to avoid metabolic decompensation. This can 
be especially challenging in pediatric patients due to 
cooperation or perhaps difficult IV access. The 
anesthesiologist should consider risk: benefit of 
utilizing such anesthetic agents such as volatile 
anesthetics, neuromuscular blocking agents, and 
propofol. This manuscript will consider a pediatric 
patient with MCADD who presented to our pediatric 
hospital and received a general anesthetic following 
the guidelines created by a multidisciplinary team 
consisting of anesthesiology, genetics, and pediatric 
surgery. 
Brief Report 
A 19 month old 11.7kg male with a history of 
MCADD was admitted for possible bilateral 
orchiopexy for undescended testes. He was diagnosed 
with MCADD by a newborn screen completed in the 
state of his birth. He was seen in our pre-operative 
clinic where a clear note was written in the patient’s 
record including recommendations by the genetics 
team for management, guided by our institution’s 
metabolic protocol.  
The patient was admitted the day before by the 
genetics service and had an IV placed with D10 ½ 
normal saline running at 45ml/hr (glucose infusion 
rate (GIR) of 6.4). He was given 250 mg of 
levocarnitine intravenously the morning of surgery. 
Other preoperative considerations for this patient 
included avoiding muscle relaxants and propofol; the 
genetics team recommended avoidance of 
benzodiazepines, barbiturates, and neuromuscular 
blocking agents.  Standard American Society of 
Anesthesiologists (ASA) monitors (16) were used 
which included: 3 lead electrocardiogram, 
noninvasive blood pressure monitor, pulse oximetry, 
and capnography. Intravenous induction of anesthesia 
was completed with ketamine 50 mg and fentanyl 20 
mcg. He was easily intubated with a 4.0 endotracheal 
tube without the use of paralytics. Sevoflurane was 
used for anesthesia maintenance. The patient was 
extubated deep after no true testes were found, and 
the procedure was terminated. He was brought to the 
post anesthesia care unit (PACU) with continued D10 
fluid. After an uneventful PACU stay, he was 
discharged to the floor with D10 fluid until he was 
able to tolerate solid food. He was discharged by the 
genetics team later that day with no complications 
noted in the electronic medical record. 
Discussion 
In 2013 a multidisciplinary team was 
assembled at our institution to create preoperative 
guidelines and best practice recommendations for 
children with inborn errors of metabolism.  The team 
consisted of pediatric anesthesiologists, geneticists, 
and pediatric surgeons. They identified best 
preoperative practices with the dual aim to prevent 
procedural cancellations or metabolic crises.  
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Per our institutional protocol, if a child with 
MCADD needs a procedure requiring an anesthetic, 
he/she is referred to our preoperative evaluation clinic 
for a pre-anesthetic evaluation.  Part of this evaluation 
consists of direct communication with the genetics 
team for their specific recommendations, i.e. unique 
preoperative labs, medications and IV fluid 
management. The day before surgery, if indicated, the 
patient will be admitted to the hospital and an IV 
placed prior to becoming NPO. Ideally, to minimize 
prolonged NPO times due to changes in the schedule, 
the patient will be the first case in the room.  
The NPO policy for our institution follows the 
ASA NPO guidelines which is 2 hours for clear 
liquids; 4 hours for breast milk; 6 hours for formula; 
and 6-8 hours for solid food depending on the fat 
contents (17). For IV fluids, D10 (or D12.5) ½ NS + 
2mEQ/100mL KCl to run with glucose infusion rate 
(GIR) 8-9 (mg/kg/min). Glucose infusion rate is 
derived from factors such as the IV fluid infusion rate, 
the patient’s weight, and % of dextrose in the 
solution. A GIR of 5-8 is considered an average rate 
to maintain euglycemia (18). If additional fluids are 
required to replace losses, normal saline or Plasma-
Lyte is preferred over Ringer’s Lactate since this may 
theoretically increase acidosis as well as metabolic 
load on dysfunctional mitochondria.  
Our institutional metabolic disorders guidelines 
also include recommendations for intraoperative 
anesthetic management. With regards to medications, 
drugs that are metabolized into odd chain fatty acids 
should be used cautiously in patients with MCADD 
which include: succinylcholine, atracurium, 
mivacurium, and propofol (as it is high in 
polyunsaturated fats) (19, 20). Some patients may be 
more sensitive and show prolonged effects to central 
nervous system depressants, and therefore it is 
recommended to delay extubation until complete 
muscle strength as returned. Specific MCADD 
preoperative fluid recommendations advocate the use 
of carnitine if it is currently prescribed.  
 
Figure 1. Medium-chain acyl-CoA dehydrogenase (MCAD) is one of the enzymes responsible for dehydrogenation of fatty acids as 
they cycle through the beta-oxidation spiral.By Modre-Osprian, Robert; Osprian Ingrid; Tilg, Bernhard; Schreier, Gunter; Weinberger, 
Klaus; and Graner, Armin.    
Wikimedia Commons, Creative Commons Attribution-Share Alike 3.0 Unported license 
https://commons.wikimedia.org/wiki/File:BetaOxidationSpiral 
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Authors agree that the  preoperative 
management of MCADD requires strategic planning 
to limit NPO times thus avoid depleting glucose 
stores with resulting metabolic decompensation (2, 5–
7, 12). Table 2 provides a side by side comparison of 
anesthetic recommendations for MCADD. While 
these recommendations advocate for glucose 
containing IV fluids to start preoperatively and 
continue into the  preoperative period, there is no 
overall consensus of the specific type of fluid nor the 
GIR (2, 5–7, 12). Our recommendations include 
guidelines on a specific GIR, as it provides a measure 
of how quickly a patient receives carbohydrates. 
While caution has been issued regarding the use of 
propofol, volatile anesthetics, and muscle relaxants in 
the context of MCADD, there are case reports of 
uneventful anesthetics (2, 6, 7).  
Our case report considers an uneventful 
anesthetic utilizing our institution’s evidenced based 
metabolic guidelines which are supported by others in 
the literature. The British Inherited Metabolic Disease 
Group provides specific  preoperative guidelines for 
MCADD patients which include recommendations on 
NPO times and IV/oral glucose replacement (12). 
Created in 2013, the BIMDG guidelines formalized 
practices in the United Kingdom which included the  
preoperative use of 10% glucose solutions (5, 12). 
Like the BIMDG guidelines, our institutional 
recommendations share multidisciplinary 
preoperative planning, limiting NPO times, 
pre/intra/postoperative use of 10% glucose solutions, 
and the resumption of a normal diet as soon as 
feasibly possible.  
 Allen et al performed a retrospective chart 
review of 14 patients with MCADD who received a 
total of 20 general anesthetics over a 17 year period 
(5). The small number reflects that although MCADD 
may be the most common inherited form of error in 
fatty acid oxidation, it is not a disease process that 
requires multiple procedures for satisfactory quality 
of life. A majority of these children received glucose 
containing fluids preoperative hydration per BIMDG 
recommendations, with 5 reported cases of 
hyperglycemia (no hypoglycemia or 
decompensation). Propofol and volatile anesthetics 
were given, often in combination for these 
procedures, uneventfully. There was, however, 1 
reported case of delayed offset of atracurium; and the 
authors urge the use of twitch monitoring if 
neuromuscular blocking agents are used. Allen et al 
strongly advocate preoperative glucose 
supplementation following BIMDG, without making 
specific recommendations on medications to 
absolutely avoid. Our case report reflects similar 
results, no incidence of metabolic decompensation 
when glucose supplementation was given, and the 
safe use of volatile anesthetics for a brief procedure. 
The three decades following Stanley’s 
description of MCADD has greatly expanded the 
medical communities understanding of this disease. 
Table 1: Systemic consequences of medium-chain acyl-CoA dehydrogenase deficiency (MCADD). 
 
Organ System Symptom 
Central Nervous System  Coma 
 Encephalopathy  
 Lethargy  
 Seizures 
 Sudden death 
Cardiac  Arrhythmia 
 Cardiovascular arrest 
Gastrointestinal  Abnormal liver function tests 
 Hepatomegaly 
 Peripheral lobular fatty liver 
 Vomiting 
Metabolic  Hyperammonemia 
 Impaired ketogenesis with hypoketotic hypoglycemia 
 Metabolic acidosis 
 Secondary carnitine deficiency  
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Apart from dietary management, future treatment may 
include gene therapy as trials are promising using 
fiberblast cultures using in vitro studies (21).  
Anesthetic medications,  preoperative guidelines, and 
Table 2: Comparison of anesthetic recommendations for MCADD 







 Patient admitted the 
night before surgery 
to commence IV 
fluid therapy 
 D10 (or D12.5) ½ NS + 
2mEQ/100mL KCl to run with 
GIR 8-9  
(weight x GIR x 0.6);  
 If extra fluids are to be required 
to replace losses, NS is preferred 
over Ringer’s Lactate 
Recommend avoiding 
benzodiazepines, barbiturates, 










 Feed the child at the 
time you would feed 




 Discontinue the 
intravenous infusion 
ONLY after the 




 IVF to start at time operations 
starts 
 10% glucose 0.45% saline 
 Fluid/24 hours = 100ml/kg for 
1st10kg then 50 ml/kg for next 
10kg then 20ml/kg 
thereafter. Potassium should be 
added to this solution 10 mmol 
in 500 ml  




Allen et al.  Recommends following 
BIMDG guidelines 
Recommends following BIMDG 
guidelines 
 May be safest to avoid 
propofol; or use 2% 
formulation to limit fatty acid 
load 
 High dose opiate with low 
dose volatile anesthetic 
 Recommends antiemetics to 
control post op nausea 
vomiting 
 Cautions use of volatile 
anesthetics and propofol 
Dearlove et al. Recommend that children 
for the afternoon 
operating lists should 
have a light breakfast and 
a glucose drink at 1100 h 
 
 10% glucose infusion 
 
Reported using thiopental and local 
anesthetic uneventfully   
Justiz et al.  Limit NPO status to 
2–4 h 




 Preoperative intravenous 
catheter placement  
 5%  dextrose in lactated 
Ringer’s 
 Consider adding carnitine  
Reported using midazolam, 
propofol, sevoflurane uneventfully  
Wang et al.  Limit NPO status to 
12 hours max 
 10% glucose to start 
preoperatively 
 Considering giving carnitine if 
neurologic status changes 
 Preop: assess medical history, 
neurologic status, 
coagulations profile, and 
blood glucose levels 
 Recommends avoiding 
succinylcholine 
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glycemic control would benefit from future 
prospective studies to optimize recommendations (5). 
Currently, an IRB has been submitted at our 
institution to prospectively study the impact of these 
metabolic guidelines and safety with anesthesia. 
Conclusion 
MCADD is the most common inherited 
disorder of mitochondrial fatty acid oxidation. 
Roughly 1/3 of affected individuals are asymptomatic 
throughout life, but will remain at risk for metabolic 
decompensation in times of of increased energy 
demands such as: fasting, stress due to surgery, 
pregnancy, or illness. Although there is no diagnostic 
stigmata of MCADD, those in acute decompensation 
can exhibit hypoketotic hypoglycemia, 
encephalopathy, hepatomegaly, vomiting, seizures, 
coma, or cause death. Multidisciplinary preoperative 
planning is highly advisable for MCADD patients 
requiring anesthesia. Ideally they should be the first 
case of the day, and preoperative dextrose containing 
IV fluids started to avoid metabolic decompensation. 
This can be especially challenging in pediatric 
patients due to cooperation or perhaps difficult IV 
access. The anesthesiologist should consider risk: 
benefit of utilizing such anesthetic agents such as 
volatile anesthetics, neuromuscular blocking agents, 
and propofol. 
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